Sanuwave Health, Inc. · NASDAQ:SNWV
Sanuwave Health — Q2 2024 Earnings Presentation
8 slides from Sanuwave Health's earnings presentation, Aug 13, 2024
Slide 1: Q2 FY2024
(6) SANUWAVE Wound Care Technologies Q2 FY2024 August 13, 2024
Slide 2: Live Presentation and Dial-in Information
Live Presentation Tuesday, August 13, 2024, 8:30 AM (ET) Participant Dial-in Information Toll Free: 1-800-579-2543 Toll/International: 1-785-424-1789 OR click the link for instant telephone access to the event. https://viavid.webcasts.com/starthere.jsp?ei=1684060&tp_key=35ff7216a3 Replay Dial-in Inf
Slide 3: Forward Looking Statements
3 Forward Looking Statements This presentation may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations and constraints, and plans for future business developm
Slide 4: Financials Q2 2024
4 Financials Q2 2024 Consistent topline growth while managing operating cost (in millions) Q2 2024 Q2 2023 YoY Revenue $7.2 $4.7 + 53% Gross Profit $5.2 $3.5 + 51% Gross Margin 73% 74% -100bp Operating Expense $3.2 $2.5 +28% Revenue Gross Profit Operating Operating Income $2.0 $0.9 +114% Income 2024
Slide 5: Improved operational results
5 Improved operational results See Non-GAAP Financial Measures disclosure included on slide 3
Slide 6: Growing UltraMist Systems & Consumables Sales
6 Growing UltraMist Systems & Consumables Sales Continuous UltraMIST revenue growth throughout 2023. Strong year on year growth in 2024. $5.0 + 67% yoy • 788 Active Systems* in $4.5 +15% seq the field at end of Q2 $4.0 2024 $3.5 • In Q2 2024 : 72 systems +68% yoy $3.0 sold (vs 49 in Q2 2023 +62% seq
Slide 7: Q3 and FY 2024 Revenue Guidance
7 Q3 and FY 2024 Revenue Guidance Q3 2024 FY 2024 REVENUE GROWTH REVENUE GROWTH 50%+ +65-75% (over $30mm) Vs Vs Q3 2023 REVENUE FY 2023 REVENUE Of $4.95 million Of $20.4 million
Slide 8: Summary
8 Summary Wound care is undergoing a payor led shift to evidence based medicine and reimbursement. This has aligned incentives for Patients, Payors, and Providers. SANUWAVE is in a prime position to benefit: § Approved products protected by strong IP § Strong existing reimbursement with room to impr